IQVIA (NYSE:IQV) PT Raised to $251.00

IQVIA (NYSE:IQV) had its price target hoisted by Robert W. Baird from $235.00 to $251.00 in a research report released on Tuesday, Benzinga reports. Robert W. Baird currently has a neutral rating on the medical research company’s stock.

Several other research analysts also recently weighed in on IQV. Barclays dropped their target price on IQVIA from $275.00 to $255.00 and set an overweight rating on the stock in a research note on Friday, June 28th. The Goldman Sachs Group assumed coverage on IQVIA in a research note on Thursday, June 6th. They set a buy rating and a $270.00 target price on the stock. Truist Financial dropped their target price on IQVIA from $297.00 to $292.00 and set a buy rating on the stock in a research note on Friday, May 3rd. Evercore ISI dropped their target price on IQVIA from $250.00 to $230.00 and set an outperform rating on the stock in a research note on Tuesday, July 9th. Finally, StockNews.com upgraded IQVIA from a hold rating to a buy rating in a research note on Monday, July 15th. Four analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of Moderate Buy and a consensus price target of $263.56.

IQVIA Trading Up 3.2 %

Shares of NYSE:IQV opened at $239.67 on Tuesday. IQVIA has a 12-month low of $167.42 and a 12-month high of $261.73. The business’s fifty day simple moving average is $220.23 and its 200-day simple moving average is $229.41. The company has a market capitalization of $43.69 billion, a PE ratio of 32.74, a P/E/G ratio of 2.24 and a beta of 1.49. The company has a current ratio of 0.85, a quick ratio of 0.88 and a debt-to-equity ratio of 1.80.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The business had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. During the same period last year, the business posted $2.22 EPS. The business’s revenue was up 2.3% compared to the same quarter last year. As a group, equities research analysts predict that IQVIA will post 10.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On IQVIA

Several institutional investors and hedge funds have recently modified their holdings of IQV. Mutual Advisors LLC acquired a new position in shares of IQVIA in the 4th quarter valued at about $217,000. HB Wealth Management LLC lifted its holdings in shares of IQVIA by 38.7% in the 4th quarter. HB Wealth Management LLC now owns 2,202 shares of the medical research company’s stock valued at $509,000 after buying an additional 614 shares during the period. CVA Family Office LLC acquired a new position in shares of IQVIA in the 4th quarter valued at about $43,000. Investment Research & Advisory Group Inc. lifted its holdings in shares of IQVIA by 1.2% in the 4th quarter. Investment Research & Advisory Group Inc. now owns 17,405 shares of the medical research company’s stock valued at $4,027,000 after buying an additional 210 shares during the period. Finally, WASHINGTON TRUST Co lifted its holdings in shares of IQVIA by 0.3% in the 4th quarter. WASHINGTON TRUST Co now owns 107,432 shares of the medical research company’s stock valued at $24,858,000 after buying an additional 355 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.